Skip to main contentSkip to navigationSkip to search

Curasight to present at Redeye Fight Cancer Seminar

January 16, 2023


Copenhagen, Denmark, 16 January 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company at Redeye Fight Cancer Seminar Outlook - January 19, 2023.

The presentation will include an update on the momentum and business progress made by the company and look ahead at the coming news flow for the new year. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer.

The presentation will be webcasted live 15:05-15:25 (CET), Thursday January 19, 2023.

For more information please click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.